# Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate

> **NCT02786563** · — · WITHDRAWN · sponsor: **AbbVie**

## Conditions studied

- Rheumatoid Arthritis (RA)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02786563
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-09-30
- **Primary completion:** 2018-11-21
- **Final completion:** 2018-11-21
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Strategic considerations
- **Last updated:** 2018-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02786563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02786563, "Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02786563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*